Enzalutamida en este contexto (CPRC): ¿cuáles son los pacientes? - page 9

AFFIRM Overall Survival:

Median of 4.8 months

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6,7,8 10,11,12,13,14,15,16,17,18,19,...42